Literature DB >> 33652860

A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms.

Ana Guijarro-Hernández1, José Luis Vizmanos1,2.   

Abstract

Ph-negative myeloproliferative neoplasms (polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)) are infrequent blood cancers characterized by signaling aberrations. Shortly after the discovery of the somatic mutations in JAK2, MPL, and CALR that cause these diseases, researchers extensively studied the aberrant functions of their mutant products. In all three cases, the main pathogenic mechanism appears to be the constitutive activation of JAK2/STAT signaling and JAK2-related pathways (MAPK/ERK, PI3K/AKT). However, some other non-canonical aberrant mechanisms derived from mutant JAK2 and CALR have also been described. Moreover, additional somatic mutations have been identified in other genes that affect epigenetic regulation, tumor suppression, transcription regulation, splicing and other signaling pathways, leading to the modification of some disease features and adding a layer of complexity to their molecular pathogenesis. All of these factors have highlighted the wide variety of cellular processes and pathways involved in the pathogenesis of MPNs. This review presents an overview of the complex signaling behind these diseases which could explain, at least in part, their phenotypic heterogeneity.

Entities:  

Keywords:  CALR; JAK2; MPL; TPOR; myeloproliferative neoplasms; signaling pathways

Year:  2021        PMID: 33652860     DOI: 10.3390/cancers13050984

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Min Wang; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

Review 2.  Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Authors:  Maria Teresa Bochicchio; Valeria Di Battista; Pietro Poggio; Giovanna Carrà; Alessandro Morotti; Mara Brancaccio; Alessandro Lucchesi
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

3.  Advances in the Knowledge of the Molecular Pathogenesis of High-Prevalence Tumors and Its Relevance for Their Future Clinical Management.

Authors:  Marta Rodríguez; Ion Cristóbal
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

Review 4.  Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.

Authors:  Vikas Bhuria; Conny K Baldauf; Burkhart Schraven; Thomas Fischer
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.